Rhythm Pharmaceuticals (RYTM) has just reported Q1 2026 results, with trailing twelve month revenue of about US$189.8 million and a net loss of roughly US$201.9 million, which translates into basic EPS of US$3.11 in losses. Over recent quarters, revenue has moved from US$41.8 million in Q4 2024 to US$57.3 million in Q4 2025, while quarterly basic EPS losses have ranged between about US$0.73 and US$0.82 per share. For investors, the focus is now on whether that expanding top line can ultimately support healthier margins and a clearer path toward profitability.

See our full analysis for Rhythm Pharmaceuticals.

With the latest figures available, the next step is to see how this margin profile aligns with the widely followed growth and risk narratives around Rhythm Pharmaceuticals and where those views may need to be reconsidered.

US$189.8m trailing revenue against US$201.9m loss

• Over the last twelve months to Q1 2026, Rhythm booked about US$189.8 million of revenue while posting a net loss of roughly US$201.9 million, so every US$1 of revenue still sits against about US$1 of loss.
• Consensus narrative highlights a growing patient base and long patent life, and this loss profile tests how quickly that can matter in practice.
  • Revenue on a trailing basis has moved from US$130.1 million at Q4 2024 to US$189.8 million at Q4 2025, which lines up with the idea of a larger commercial opportunity, but net loss stayed close to US$200 million, showing costs are still running at a similar scale to revenue.
  • Analysts expecting revenue growth of about 39.8% a year and earnings growth of 74.26% a year are effectively assuming a sharp improvement from this current US$201.9 million loss position, so tracking whether losses shrink from here is key for anyone leaning on that bullish story.

Rhythm’s recent move toward higher revenue with heavy losses gives bulls plenty to point to, but also leaves a lot of work for the profit turnaround they are banking on, so it is worth seeing how that debate plays out in the full bull case. 🐂 Rhythm Pharmaceuticals Bull Case

Revenue ramp, losses still around US$48 to 55m a quarter

• Across 2025, quarterly revenue went from US$32.7 million in Q1 to US$57.3 million in Q4, while quarterly net losses over the same period stayed in a tight band between about US$48.0 million and US$54.3 million.
• Bears worry that rising sales are not translating to better profitability yet, and the quarterly pattern gives some support to that concern.
  • Even as revenue stepped up from US$41.8 million in Q4 2024 to US$57.3 million in Q4 2025, net loss only shifted from US$44.6 million to US$48.8 million, so losses remain sizable in absolute terms relative to revenue.
  • With losses having grown at about 19.3% a year over the past five years and analysts expecting profitability within roughly three years, the current run rate of US$48 to 55 million in quarterly losses shows how much cost discipline or gross margin improvement bears will want to see before treating that timeline as realistic.

Skeptics point to the steady US$50 million style quarterly losses as a key reason to stay cautious until Rhythm shows clearer traction on margins and cost control. 🐻 Rhythm Pharmaceuticals Bear Case

High-growth forecasts meet rich 33.2x P/S tag

• At a share price of US$92.31, Rhythm trades on about 33.2x P/S versus 10.8x for the US biotech industry and 8.7x for peers, while model estimates put DCF fair value at roughly US$435.86 and the allowed consensus target at US$137.80.
• What stands out is how the bullish and cautious views both lean on these same valuation gaps but draw different conclusions from them.
  • Supporters point to revenue projected to grow 39.8% a year and earnings growth of 74.26% a year, arguing that a DCF fair value around US$435.86 and a price target of US$137.80 leave room for upside from US$92.31 if those assumptions hold.
  • Critics counter that a 33.2x P/S multiple, which is roughly 3x the industry average, already prices in a lot of that growth, so any delay in the path from a trailing US$201.9 million loss to future profit could make this rich multiple harder to justify.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Rhythm Pharmaceuticals on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If this mix of optimism and caution feels familiar, do not sit on the sidelines. Instead, check the upside drivers for yourself with the 3 key rewards.

See What Else Is Out There

Rhythm’s revenue is growing, but quarterly losses of around US$48 to 55 million and a rich 33.2x P/S multiple highlight meaningful risk for cautious investors.

If you want ideas where pricing looks more forgiving and financial profiles may feel more balanced, check out 72 resilient stocks with low risk scores today and compare the trade off for yourself.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.